^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Her2-positive Lung Cancer Treated With Dedicated Drug
Excerpt:
...HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C....
Trial ID:
Source:
Title:
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxel
Excerpt:
...HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C. ...
Trial ID:
Less C2 evidence
Source:
Title:
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Published date:
10/04/2023
Excerpt:
We assessed pertuzumab + trastuzumab in a tissue-agnostic cohort of adult patients with human epidermal growth factor receptor 2 (HER2)-amplified and/or -overexpressed and/or -mutated solid tumors...HER2 mutations alone (n = 83) had been treated...In patients with HER2 mutations alone, ORR was 6.0% (5/83, 95% CI, 2.0 to 13.5).
DOI:
10.1200/JCO.22.02636
Trial ID:
